Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA7 | P36544 | 14/20 | 0.45 |
| ▸ | KCNH2 | Q12809 | 13/20 | 0.45 |
| ▸ | CHRNA1 | P02708 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.44 |
| ▸ | MAP3K8 | P41279 | 1/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.40 |
| ▸ | CSF1R | P07333 | 1/20 | 0.37 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6190172 | 0.95 | CHRNA7 (0.44) | CHRNA7KCNH2CHRNA1CYP1A2CYP3A4 | |
| SCHEMBL6207286 | 0.94 | CHRNA7 (0.40) | CHRNA7KCNH2CHRNA1CYP1A2CYP3A4 | |
| SCHEMBL6399220 | 0.89 | CHRNA7 (0.43) | CHRNA7KCNH2CHRNA1CYP1A2CYP3A4 | |
| SCHEMBL6403862 | 0.88 | CHRNA7 (0.42) | CHRNA7KCNH2CHRNA1CYP1A2CYP3A4 | |
| SCHEMBL6189562 | 0.87 | CHRNA7 (0.44) | CHRNA7KCNH2CHRNA1CYP1A2CYP3A4 | |
| SCHEMBL6403620 | 0.85 | CHRNA7 (0.48) | CHRNA7KCNH2CHRNA1CYP1A2CYP3A4 | |
| SCHEMBL15598681 | 0.85 | CHRNA7 (0.44) | CHRNA7KCNH2CHRNA1CYP1A2CYP3A4 | |
| SCHEMBL6207045 | 0.85 | MAP2K2 (0.47) | CHRNA7KCNH2CHRNA1CYP1A2CYP3A4 | |
| SCHEMBL29371646 | 0.85 | MAP2K2 (0.47) | CHRNA7KCNH2CHRNA1CYP1A2CYP3A4 | |
| SCHEMBL6189558 | 0.83 | CHRNA7 (0.51) | CHRNA7KCNH2CHRNA1CYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050004186-A1 | MEK inhibiting compounds | PFIZER INC | 2005-01-06 | — | — | US | claimed |
| EP-1578736-A1 | MEK INHIBITING OXA- AND THIA-DIAZOL-2-YL-PHENYLAMINE DERIVATIVES | Warner-Lambert Company LLC (US) | 2005-09-28 | — | — | EP | disclosed |
| US-20050004186-A1 | MEK inhibiting compounds | PFIZER INC | 2005-01-06 | — | — | US | disclosed |
| US-20050002859-A1 | COX-2-targeted imaging agents | VANDERBILT UNIVERSITY (US) | 2005-01-06 | — | — | US | disclosed |
| WO-2004056789-A1 | MEK INHIBITING OXA- AND THIA-DIAZOL-2-YL PHENYLAMINE DERIVATES | WARNER-LAMBERT COMPANY LLC (US) | 2004-07-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050004186-A1 | MEK inhibiting compounds | MAPK1, MAP3K1, MAPK3 | CHRNA7 4667/4885KCNH2 3852/4885CHRNA1 4381/4885 |
| US-20050002859-A1 | COX-2-targeted imaging agents | PTGS2, PTGES2, PTGER2 | CHRNA7 3858/4885KCNH2 4710/4885CHRNA1 4260/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.